Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 158 clinical trials
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined by the

  • 10 views
  • 21 Jan, 2021
  • 36 locations
DC Vaccination in CML

residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML (chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission. These patients can be included

tyrosine
residual tumor
remission
leukemia
bcr-abl protein
  • 6 views
  • 22 Jan, 2021
  • 1 location
Frontline Asciminib Combination in Chronic Phase CML

Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+) and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A <4 week

nilotinib
philadelphia chromosome
asciminib
imatinib
dasatinib 100 mg
  • 0 views
  • 17 Sep, 2020
  • 37 locations
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

imatinib (Glivec®) in pretreated Philadelphia chromosome- positive (Ph+)/BCR-ABL+ CML patients in chronic phase.

philadelphia chromosome
leukemia
gleevec
imatinib
interferon
  • 11 views
  • 07 Nov, 2020
  • 1 location
Treatment Modification Based on Early Assessment of CML Patients

The investigators will check the feasibility of using early molecular response for making treatment decisions. Patients diagnosed with chronic myeloid leukemia will commence imatinib treatment

nilotinib
philadelphia chromosome
imatinib
tyrosine
philadelphia chromosome positive chronic myelogenous leukemia
  • 5 views
  • 08 Nov, 2020
  • 1 location
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

(EPA) when given daily in combination with a Tyrosine Kinase Inhibitor (TKI) in subjects with Chronic Myeloid Leukemia (CML) in chronic stable phase. The recommended Phase II dose will be the maximum

  • 0 views
  • 04 Nov, 2020
  • 1 location
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

relapse (loss of MMR) in CML patients, who discontinue ABL tyrosine kinase inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5, or MR5).

  • 22 views
  • 23 Sep, 2020
  • 48 locations
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia

The treatment of CML and the expected survival has been revolutionised since the introduction of tyrosine kinase inhibitors (TKIs) such as nilotinib. Despite their effectiveness, these drugs

nilotinib
lipase
imatinib
potassium
interferon
  • 10 views
  • 07 Nov, 2020
  • 1 location
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

The results of the International Randomized Study of Interferon and STI571 (IRIS) trial indicate that in patients with chronic phase CML treated with first line imatinib, achievement of a

nilotinib
philadelphia chromosome
lipase
imatinib
potassium
  • 10 views
  • 17 Jan, 2021
  • 1 location
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia

  • 38 views
  • 29 Nov, 2020
  • 432 locations